By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Affimed Therapeutics AG 

Im Neuenheimer Feld 582
Heidelberg    69120   Germany
Phone: 49-6221-65307-0 Fax: 49-6221-65307-77



Company News
Affimed Therapeutics AG (AFMD) Appoints Dr. Martin Treder As Chief Scientific Officer 1/20/2015 7:32:44 AM
Affimed Therapeutics AG (AFMD) Receives EUR 2.4 Million ($3 Million) Research Grant From German Government To Fund Trispecific Abs 1/7/2015 7:56:28 AM
Affimed Therapeutics AG (AFMD) Presents Final Data For AFM13 Phase 1 Trial At American Society of Hematology 12/8/2014 8:06:44 AM
Affimed Therapeutics AG (AFMD) To Present At The Jefferies and Co. Global Healthcare Conference - London 11/12/2014 10:10:57 AM
Affimed Therapeutics AG (AFMD) Announces Third Quarter 2014 Financial Results Conference Call 11/11/2014 8:44:42 AM
Affimed Therapeutics AG (AFMD) Announces Closing Of Initial Public Offering 9/18/2014 7:48:47 AM
Affimed Therapeutics AG (AFMD) Prices IPO At $7, Below The Range 9/12/2014 7:07:32 AM
Immuno-Oncology Biotech Affimed Therapeutics AG Files For $75 Million IPO 6/30/2014 7:06:04 AM
Affimed Therapeutics AG Highlights Further Data On AFM13, A Bispecific CD30/CD16A TandAb in Development To Treat Hodgkin Lymphoma, At The 2014 American Association for Cancer Research Annual Meeting 4/10/2014 7:49:05 AM
The Leukemia & Lymphoma Society and Affimed Therapeutics AG Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 9/16/2013 11:00:04 AM